Piyasa kapalı· · CNY · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), today announced a total capital injection of RMB 1.2397 billion (approximately US$184 million) into AsymBio by Asymchem Group, Hillhouse Qirui and other investors.
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), today announced that construction of its new R&D building has officially broken ground at the Shanghai Fengxian site. The project marks a pivotal infrastructure step in strengthening AsymBio's biologics CDMO capabilities and reinforcing the Fengxian site's role as a core development-and-manufacturing hub.
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ /6821.HK), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially commenced operations. This milestone completes a Shanghai-based “Golden Triangle” footprint comprising the Zhangjiang Science & Technology Center, Jinshan Site, and Fengxian Site. The three locations integrate end-to-end CDMO capabilities from early R&D and process development through c
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.